JP2024534838A - ＮＫｐ４６結合ポリペプチド及びその使用 - Google Patents

ＮＫｐ４６結合ポリペプチド及びその使用 Download PDF

Info

Publication number
JP2024534838A
JP2024534838A JP2024512984A JP2024512984A JP2024534838A JP 2024534838 A JP2024534838 A JP 2024534838A JP 2024512984 A JP2024512984 A JP 2024512984A JP 2024512984 A JP2024512984 A JP 2024512984A JP 2024534838 A JP2024534838 A JP 2024534838A
Authority
JP
Japan
Prior art keywords
polypeptide
cancer
seq
nkp46
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534838A5 (https=
JPWO2023034740A5 (https=
Inventor
ジョン シー． ティマー
ブレンダン ピー． エッケルマン
ラジェイ エー． パンディット
ウィリアム クラゴ
フロリアン スルツマイアー
ヘザー キンケード
ナジャ カーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aatd Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of JP2024534838A publication Critical patent/JP2024534838A/ja
Publication of JP2024534838A5 publication Critical patent/JP2024534838A5/ja
Publication of JPWO2023034740A5 publication Critical patent/JPWO2023034740A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024512984A 2021-08-30 2022-08-29 ＮＫｐ４６結合ポリペプチド及びその使用 Pending JP2024534838A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163238429P 2021-08-30 2021-08-30
US63/238,429 2021-08-30
PCT/US2022/075581 WO2023034740A1 (en) 2021-08-30 2022-08-29 Nkp46-binding polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2024534838A true JP2024534838A (ja) 2024-09-26
JP2024534838A5 JP2024534838A5 (https=) 2025-08-12
JPWO2023034740A5 JPWO2023034740A5 (https=) 2025-08-12

Family

ID=84047735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512984A Pending JP2024534838A (ja) 2021-08-30 2022-08-29 ＮＫｐ４６結合ポリペプチド及びその使用

Country Status (7)

Country Link
US (1) US20250136681A1 (https=)
EP (1) EP4395895A1 (https=)
JP (1) JP2024534838A (https=)
CN (1) CN117940454A (https=)
CA (1) CA3228815A1 (https=)
TW (1) TW202319397A (https=)
WO (1) WO2023034740A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206329A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
CN120025440A (zh) * 2023-11-21 2025-05-23 南京融捷康生物科技有限公司 一种抗Nkp46的单域抗体及其用途
WO2025137555A1 (en) * 2023-12-20 2025-06-26 Omniab, Inc. Polypeptides that bind to nkp46
WO2025168114A1 (en) * 2024-02-09 2025-08-14 Shanghai Epimab Biotherapeutics Co., Ltd. Multifunctional nk cell engager
CN120574323A (zh) * 2024-02-29 2025-09-02 安升（上海）医药科技有限公司 一种抗NKp46的单域抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016207278A1 (en) * 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
US20210024631A1 (en) * 2018-03-28 2021-01-28 Orionis Biosciences, Inc. Bi-functional proteins and construction thereof
KR20210113265A (ko) * 2019-01-07 2021-09-15 인히브릭스, 인크. 변형된 il-2 폴리펩타이드를 포함하는 폴리펩타이드 및 이의 용도

Also Published As

Publication number Publication date
CA3228815A1 (en) 2023-03-09
CN117940454A (zh) 2024-04-26
EP4395895A1 (en) 2024-07-10
US20250136681A1 (en) 2025-05-01
WO2023034740A1 (en) 2023-03-09
TW202319397A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾ｉｌ－２ポリペプチドを含むポリペプチド及びその使用
JP7462611B2 (ja) Ｏｘ４０結合性ポリペプチド及びその使用
US20230235005A1 (en) Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
US20250320295A1 (en) CD8-Binding Polypeptides and Uses Thereof
JP2024534838A (ja) ＮＫｐ４６結合ポリペプチド及びその使用
US20250066477A1 (en) Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
US20240376198A1 (en) NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
WO2023004305A1 (en) Cd8-targeted modified il-2 polypeptides and uses thereof
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
TWI918596B (zh) Ox40結合多肽及其用途
RU2802070C2 (ru) Ох40-связывающие полипептиды и их применение
CN117980335A (zh) Cd8结合多肽及其用途
HK40050757A (en) Ox40-binding polypeptides and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260414